

DiscoverX

PrecisION[®] rNav1.8 Recombinant Stable Cell Line

Catalog Number CYL3050

Lot Number

See Vial

Contents 2 Vials, 2×10^6 to 4×10^6 in 1 mL

Background Information

Nav1.8 subtype selective blockers are predicted to be effective in the treatment of neuropathic pain and to be associated with fewer adverse effects than currently available therapies. Drugs for the clinical treatment of neuropathic pain can interact with other members of the voltage-gated sodium channel (Nav1) family due to their close sequence homology.

Product Information

Description Recombinant ND7-23 (rat DRG/mouse neuroblastoma hybrid) cell line expressing the rat Nav1.8 (type X voltage-gated sodium channel alpha subunit (Scn10a))

Family Sodium, Voltage-Gated

rNav1.8


Target

	Target Protein	Accession Number
1	rNav1.8	U53833
2	N/A	N/A
3	N/A	N/A
4	N/A	N/A

Species	Rat
Host Cell Type	ND7-23
Application	Electrophysiology assay (conventional and automated patch clamp platforms)
Storage	Vials are to be stored in vapor phase of liquid nitrogen

Functional Performance

ND7-23 cells expressing rNav1.8 were characterized in terms of their pharmacological and biophysical properties using whole-cell patch clamp techniques.



Electrophysiology Method	QPatch
Reference Agonist	
Reference Antagonist	Tetracaine
Antagonist IC $_{50}$ (μ M)	0.59



DiscoverX

Passage Stability

This cell line has been confirmed to be stable through at least 12 passages with no significant drop in assay window or change in pharmacology.

Mycoplasma Testing

This lot was tested and found to be free of mycoplasma contamination. Data available upon request.

Notes

Additional functional (pharmacological and electrophysiological) validation on multiple platforms is available upon request.

Additional Ligand Information

Control CompoundTetracaineVendor Name :Sigma-AldrichVendor Catalog No.T7383

Additional Background Information

N/A

Ordering: +1.510.979.1415 option 4 or e-mail CustomerServiceDRX@eurofins.com Technical support: +1.510.979.1415 option 5 or e-mail DRX_SupportUS@eurofinsUS.com General product information: www.discoverx.com

Limited Use License Agreement

These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License.

Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.